Показано 0 из 0
Дата |
---|
10.08.2022 |
09.08.2022 |
08.08.2022 |
05.08.2022 |
04.08.2022 |
03.08.2022 |
02.08.2022 |
01.08.2022 |
29.07.2022 |
28.07.2022 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
21.09
|
21.09
|
21.09
|
21.09
|
|
|
1 940.00
|
|
|
|
20.875
|
20.875
|
20.925
|
20.925
|
|
|
63.00
|
|
|
|
21.285
|
21.265
|
21.285
|
21.265
|
|
|
2 129.00
|
|
|
|
20.89
|
20.85
|
20.97
|
20.97
|
|
|
7 449.00
|
|
|
|
20.835
|
20.835
|
20.835
|
20.835
|
|
|
|
|
|
|
21.34
|
21.34
|
21.34
|
21.34
|
|
|
|
|
|
|
21.03
|
21.03
|
21.03
|
21.03
|
|
|
|
|
|
|
20.61
|
20.455
|
20.61
|
20.455
|
|
|
515.00
|
|
|
|
20.825
|
20.43
|
21.35
|
20.43
|
|
|
10 783.00
|
|
|
|
21.01
|
20.195
|
21.01
|
20.40
|
|
|
8 460.00
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.